The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

For adults and seniors: Inclusion Criteria: * Healthy adults aged 18-60 years old, and healthy seniors aged \> 60 years old; * Without vaccination history of seasonal split influenza vaccine in the recent 3 years * No traveling plan during the study period of this trial; * Be able to understand and sign the informed consent; Exclusion Criteria: * Allergic to egg products or any ingredient of the study vaccine; * Fever, influenza or acute illness on the vaccination day; * Acute stage of chronic illness; * Malignant tumor; * Immunodeficiency, includes HIV infection; * Guillain-Barre syndrome; * Administration of live attenuated vaccine within the previous 14 days; * Administration of subunit or inactivated vaccine within the previous 7 days; * Planned to participate in any other clinical trial of drug or vaccine during this study; * Received immunesuppressive treatment within the previous month, or planned for such treatment during this study; * Pregnant, or planning pregnancy; * Axillary temperature \> 37.0℃; * Any other factors that, in the judgment of the investigator, is unsuitable for this study; For infants: Inclusion Criteria: * Healthy male or female aged between 6 and 35 months; * Full-term birth, birth weight 2,500 grams or more; * Provided birth certification or vaccination card * Parent or legal guardian is able to understand and sign the informed consent; Exclusion Criteria: * Received seasonal influenza vaccine after June 30, 2012; * Acute infection within the previous week; * Allergy history, or allergic to any ingredient of the study vaccine, such as egg; * History of serious adverse reaction (SAR) to vaccine; * Autoimmune disease or immune deficiency, or administration of immunosuppressive therapy, cell toxic therapy, or inhaled corticosteroid within the previous 6 months; * Congenital malformations, developmental disorder or serious chronic disease; * Unstable condition of asthma and administration of corticosteroid in the most recent two years; * Coagulation abnormalities or disorders; * History/ family history of infantile convulsion, epilepsy, cerebropathy, or mental disease; * Without spleen; * Severe neurological diseases, such as Guillain-Barre syndrome; * Administration of blood products or investigational drug within the previous month; * Administration of live attenuated vaccine within the previous 14 days; * Administration of subunit or inactivated vaccine within the previous 7 days; * Received treatment for allergy within the previous 14 days; * on-going anti-tuberculosis therapy; * Axillary temperature \> 37.0℃ immediately before vaccination; * any other factors that, in the judgment of the investigator, is unsuitable for this study;